Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


M. Nielsen Hobbs

M. Nielsen Hobbs has more than 20 years of experience covering the pharmaceutical industry, and writes frequently about the intersection of business, regulation, science and politics. Before joining the “The Pink Sheet” he worked for Congressional Quarterly. Hobbs enjoys discussing BB-8 almost as much as he enjoys talking about 351(k).
Set Alert for Articles By M. Nielsen Hobbs

Latest From M. Nielsen Hobbs

Eggs May Be Culprit In Poor Flu Vaccine Performance This Year

US health authorities, manufacturers investigating why egg-based product appears to have lower effect in adults compared to cell-based flu vaccine.

Vaccines Manufacturing

US FDA's Abram Makes The Case For 180-Day Exclusivity Reform

Proposed trigger changes will discourage low-quality applications, not disincentivize patent challenges, deputy commissioner suggests at generic association's annual meeting.

Generic Drugs Legislation

At US Generic Association Annual Meeting, Worries About Sustainability

ANDA sponsors fret price erosion – and potential changes to 180-day exclusivity.
Pricing Debate Generic Drugs

Trump Emphasizes Foreign Drug Prices At Alex Azar's Swearing In

HHS secretary will get US drug prices 'way down … because it’s very unfair to our country,' president says. Also, 'we’re going to be very tough' on drug companies in combating the opioid crisis, Trump says.

Pricing Debate Legislation

Pricing Debate: GAO Report On Rx Profits Offers Ammunition To Both Sides

Sen. Sanders and Rep. Cummings requested the study, which notes industry's healthy margins and offers concerns about mergers – but emphasizes the increasing cost of R&D.

Pricing Debate Legislation

Orphan Drug Tax Credit Defense Adds To NORD's Legislative Challenges

Republican tax reform proposal would eliminate research credit; NORD already had its hands full countering 'misinformation' about impact of orphan drugs on drug spend; critics on Capitol Hill argue sponsors are gaming the system.

Rare Diseases Legislation
See All